New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges

This book illustrates some of the most recent research efforts that have been made in lowering plasma cholesterol levels in patients with CVD. Selected articles aimed to illuminate advances and urgent challenges in the management of CVD, including disease management using statin-combined therapeutic...

Full description

Saved in:
Bibliographic Details
:
Year of Publication:2019
Language:English
Physical Description:1 electronic resource (116 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03009nam-a2200913z--4500
001 993548296904498
005 20231214133455.0
006 m o d
007 cr|mn|---annan
008 202102s2019 xx |||||o ||| 0|eng d
020 |a 3-03921-677-5 
035 |a (CKB)4100000010106198 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/54599 
035 |a (EXLCZ)994100000010106198 
041 0 |a eng 
100 1 |a Bakillah, Ahmed  |4 auth 
245 1 0 |a New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges 
246 |a New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases 
260 |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2019 
300 |a 1 electronic resource (116 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a This book illustrates some of the most recent research efforts that have been made in lowering plasma cholesterol levels in patients with CVD. Selected articles aimed to illuminate advances and urgent challenges in the management of CVD, including disease management using statin-combined therapeutic strategies. 
546 |a English 
653 |a apolipoprotein 
653 |a lipids 
653 |a risk stratification 
653 |a proprotein convertase subtilisin-kexin type 9 (PCSK9) 
653 |a vaspin 
653 |a sphingolipids 
653 |a PCSK9 
653 |a ceramides 
653 |a atrial fibrillation 
653 |a circular RNA 
653 |a STEMI 
653 |a cholesterol 
653 |a lipoproteins 
653 |a cardiovascular disease (CVD) 
653 |a coronary artery bypass grafting 
653 |a atherosclerosis 
653 |a statin 
653 |a LDL subfractions 
653 |a acute kidney injury 
653 |a dyslipidemia 
653 |a gene expression 
653 |a NSTEMI 
653 |a NAFLD 
653 |a hyperlipidemia 
653 |a nonstatin 
653 |a cholesteryl ester transfer protein 
653 |a low-density lipoprotein cholesterol 
653 |a anacetrapib 
653 |a HDL 
653 |a acute coronary syndrome 
653 |a miRNA 
653 |a cardiovascular risk 
653 |a pleiotropic actions 
653 |a genetic 
653 |a ABCA1 
653 |a sdLDL 
653 |a cardiovascular disease 
653 |a proprotein convertase subtilisin/kexin type 9 
653 |a inclisiran 
653 |a reverse cholesterol transport 
653 |a sterol 
653 |a small interfering RNA (siRNA) 
653 |a RNA-binding proteins 
653 |a cardiovascular diseases 
653 |a NASH 
653 |a low-density lipoprotein-cholesterol (LDL-C) 
653 |a stroke 
653 |a nutrigenetics 
653 |a type 2 diabetes 
653 |a statins 
653 |a sphingomyelin 
653 |a hepatic fibrosis 
653 |a diabetes 
776 |z 3-03921-676-7 
906 |a BOOK 
ADM |b 2024-02-27 23:13:09 Europe/Vienna  |f system  |c marc21  |a 2020-02-01 22:26:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338771650004498&Force_direct=true  |Z 5338771650004498  |b Available  |8 5338771650004498